| Literature DB >> 30446740 |
Lohith Gowda1, Mithun Shah2, Ifra Badar3, Qaiser Bashir3, Nina Shah4, Krina Patel5, Rashmi Kanagal-Shamanna6, Rohtesh Mehta3, Donna M Weber5, Hans C Lee5, Elisabet E Manasanch5, Abdul Shah3, Sheeba K Thomas5, Simrit Parmar3, Yago Nieto3, Robert Z Orlowski5, Richard Champlin3, Muzaffar H Qazilbash7.
Abstract
Primary plasma cell leukemia (pPCL) is a rare and aggressive variant of multiple myeloma (MM) with poor long-term survival after cytotoxic chemotherapy. Many novel drugs have revolutionized the treatment algorithms for MM. The impact of targeted therapy, both pre- and post-autologous stem cell transplant (auto-HCT) remains an area of ongoing interest. In this study, we report outcomes post auto-HCT for pPCL and the impact of maintenance therapy posttransplant with novel agents.Entities:
Mesh：
Year: 2018 PMID： 30446740 DOI： 10.1038/s41409-018-0392-1
Source DB: PubMed Journal: Bone Marrow Transplant ISSN： 0268-3369 Impact factor: 5.483